Toshihiko Kotake

Suggest Changes
Learn More
A pilot dose-escalation study of recombinant human interleukin 12 (rhIL-12) was conducted in Japanese patients with advanced malignancies. Cohorts of three patients received escalating doses of(More)
OBJECTIVES We compared the prophylactic efficacy and safety of epirubicin (EPI) in primary superficial bladder cancer. METHODS The major inclusion criteria were primary superficial bladder tumour(More)
This study was undertaken to determine the clinical usefulness of NMP22 (Nuclear Matrix Protein 22) as a urinary marker for the surveillance of bladder cancer, especially in comparison with that of(More)